UnknownPhase 3

Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

South Korea342 participantsStarted 2021-11-19

Plain-language summary

This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic Episode of Schizophrenia.

Who can participate

Age range19 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Psychiatric Criteria
✕. Treatment-related Criteria
✕. Other

What they're measuring

Positive And Negative Syndrome Scale(PANSS) total score

Timeframe: at Week 6

Trial details

NCT IDNCT05168007

SponsorWhanin Pharmaceutical Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-07-17

View on ClinicalTrials.gov More Schizophrenia trials